PE20011179A1 - Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma - Google Patents

Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma

Info

Publication number
PE20011179A1
PE20011179A1 PE2001000297A PE2001000297A PE20011179A1 PE 20011179 A1 PE20011179 A1 PE 20011179A1 PE 2001000297 A PE2001000297 A PE 2001000297A PE 2001000297 A PE2001000297 A PE 2001000297A PE 20011179 A1 PE20011179 A1 PE 20011179A1
Authority
PE
Peru
Prior art keywords
spheres
estavudine
globules
small spheres
refers
Prior art date
Application number
PE2001000297A
Other languages
English (en)
Inventor
Robert Abramowitz
Denise M O'donoghue
B Jain Nemichand
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20011179A1 publication Critical patent/PE20011179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A PEQUENAS ESFERAS O GLOBULOS FORMADOS POR EXTRUSION Y CONFORMACION DE PEQUENAS ESFERAS QUE COMPRENDE DE 33% A 67% DE ESTAVUDINA, UN AGENTE FORMADOR DE ESFERAS O GLOBULOS COMO CELULOSA MICROCRISTALINA, CARBOXIMETILCELULOSA DE SODIO, ALMIDON DE MAIZ; DE 0,5% EN PESO A 3% EN PESO DE ESTEARATO DE MAGNESIO SUFICIENTE PARA ESTABILIZAR ESTAVUDINA CONTRA LA DEGRADACION DURANTE EL PROCESO DE EXTRUSION-FORMACION DE PEQUENAS ESFERAS O GLOBULOS; ADEMAS COMPRENDE UN DILUYENTE COMO LACTOSA, FOSFATO DICALCICO, MANITOL Y ALMIDON DE MAIZ; UNA CAPA DE SELLADO QUE COMPRENDE UN FORMADOR DE PELICULA (HIDROXIPROPILMETILCELULOSA, DIHIDROXIPROPILCELULOSA) Y UN ANTIADHERENTE (TALCO, CELULOSA MICROCRISTALINA, ESTEARATO DE MAGNESIO), UNA CAPA DE LIBERACION MODIFICADA QUE COMPRENDE UN MATERIAL AISLANTE POLIMERICO (POLIMETACRILATO, ETILCELULOSA) Y UN PLASTIFICANTE (MONOGLICERIDOS ACILADOS). TAMBIEN SE REFIERE A UN METODO PARA FORMAR ESFERAS O GLOBULOS. TAMBIEN SE REFIERE A UNA FORMA DE DOSIFICACION QUE COMPRENDE ADEMAS DIDANOSINA. LAS ESFERAS O GLOBULOS SON ADECUADOS PARA PREPARAR FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA CAPACES DE PROPORCIONAR NIVELES DE ESTAVUDINA EN SANGRE DURANTE 24 HORAS CON UNA SOLA DOSIS
PE2001000297A 2000-03-30 2001-03-30 Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma PE20011179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
PE20011179A1 true PE20011179A1 (es) 2001-12-06

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000297A PE20011179A1 (es) 2000-03-30 2001-03-30 Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma

Country Status (26)

Country Link
US (1) US7135465B2 (es)
EP (1) EP1267879A2 (es)
JP (1) JP2003528905A (es)
KR (1) KR20030011805A (es)
CN (1) CN1187052C (es)
AR (1) AR027748A1 (es)
AU (1) AU2001249591A1 (es)
BG (1) BG107157A (es)
BR (1) BR0109602A (es)
CA (1) CA2404687A1 (es)
CZ (1) CZ20023003A3 (es)
EE (1) EE200200564A (es)
GE (1) GEP20043285B (es)
HU (1) HUP0302631A2 (es)
IL (1) IL151475A0 (es)
LT (1) LT5045B (es)
LV (1) LV12939B (es)
MX (1) MXPA02009534A (es)
NO (1) NO20024645D0 (es)
NZ (1) NZ522250A (es)
PE (1) PE20011179A1 (es)
PL (1) PL366089A1 (es)
RU (1) RU2239435C2 (es)
SK (1) SK12822002A3 (es)
WO (1) WO2001074329A2 (es)
ZA (1) ZA200207760B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN1662223A (zh) * 2002-06-27 2005-08-31 西拉格股份公司 含水溶性活性成分的球形微丸
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
KR20080053317A (ko) * 2005-08-31 2008-06-12 씨아이피엘에이 엘티디. 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
US20170209385A1 (en) * 2014-07-17 2017-07-27 Dow Global Technolgies Llc Ethylcellulose dispersion and film
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
ES2150438T3 (es) 1991-12-30 2000-12-01 Fmc Corp Composicion de esferonizacion a base de celulosa microcristalina.
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
CN1146201A (zh) 1994-03-07 1997-03-26 沃泰克斯药物股份有限公司 用作天冬氨酰蛋白酶抑制剂的磺胺衍生物
JPH11501011A (ja) 1995-02-23 1999-01-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経保護薬としての縮合ベンゾチアゾール類の利用
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
SI9620126A (sl) 1995-12-15 1999-10-31 Cryopreservation Technologies Cc (Za/Za) Spojina za kriogensko ohranjanje organov in zdravljenje virusnih ter bakterijskih infekcij
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
EP0954291B1 (en) 1996-10-25 2005-12-28 Shire Laboratories Inc. Soluble form osmotic dose delivery system
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
DE69828289T2 (de) 1997-08-11 2005-06-02 Alza Corp., Mountain View Dosierungsform für verzögerte Freisetzung eines Wirkstoffs
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6692767B2 (en) * 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
BR9813691A (pt) 1997-12-19 2000-10-10 Takeda Chemical Industries Ltd Composição farmacêutica para antagonizar o ccr5, uso do composto ou um sal deste em combinação com um inibidor de protease e/ou um inibidor da transcriptase reversa, e, processo para antagonizar o ccr5.
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
EP1089741A1 (en) 1998-06-24 2001-04-11 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
NZ514558A (en) 1999-03-31 2004-02-27 Uaf Technologies And Res Llc Viral treatment
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
AU2001249591A1 (en) 2001-10-15
CN1187052C (zh) 2005-02-02
EP1267879A2 (en) 2003-01-02
CN1420774A (zh) 2003-05-28
US20020002147A1 (en) 2002-01-03
EE200200564A (et) 2004-06-15
IL151475A0 (en) 2003-04-10
NZ522250A (en) 2004-09-24
LV12939B (en) 2003-04-20
JP2003528905A (ja) 2003-09-30
AR027748A1 (es) 2003-04-09
CA2404687A1 (en) 2001-10-11
GEP20043285B (en) 2004-07-26
WO2001074329A3 (en) 2002-05-10
LT2002099A (en) 2003-04-25
MXPA02009534A (es) 2003-05-14
WO2001074329A2 (en) 2001-10-11
BR0109602A (pt) 2004-06-29
RU2239435C2 (ru) 2004-11-10
KR20030011805A (ko) 2003-02-11
PL366089A1 (en) 2005-01-24
SK12822002A3 (sk) 2003-02-04
LT5045B (lt) 2003-08-25
NO20024645L (no) 2002-09-27
RU2002126540A (ru) 2004-03-27
ZA200207760B (en) 2004-01-30
CZ20023003A3 (cs) 2002-11-13
US7135465B2 (en) 2006-11-14
HUP0302631A2 (hu) 2003-11-28
BG107157A (en) 2003-06-30
NO20024645D0 (no) 2002-09-27

Similar Documents

Publication Publication Date Title
PE20011179A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
ES2521671T3 (es) Agente adhesivo sensible a la presión para la piel, lámina adhesiva sensible a la presión para la piel y placa frontal de un dispositivo para ostomía
Visser et al. Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films
Malcolm et al. Advances in microbicide vaginal rings
EP0307904B1 (de) Umhüllte Retardformen
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
CA2457030A1 (en) Devices including protein matrix materials and methods of making and using same
PE20001322A1 (es) Composicion multiparticula de liberacion modificada
ES2159591T3 (es) Composicion de liberacion controlada.
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
ES2162614T1 (es) Composiciones formadoras de pelicula que comprenden almidones modificados e iota-carragaenina y metodo para producir capsulas blandas usando las mismas.
JP2011504484A (ja) 膣内薬剤放出システム
CO5570656A2 (es) Liberacin controlada de una sustancia activa a un entorno rico en grasa
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
BRPI0612448A2 (pt) composição espumosa de sacarìdeo
EP1509200A1 (de) Filmförmige, zerfallsfähige zubereitungen zur wirkstoff-freisetzung und verfahren zu deren herstellung
CY1108285T1 (el) Σφαιροειδη, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις
AU2013213514B2 (en) A drug delivery system
CZ284806B6 (cs) Podkožní implantáty na bázi derivátů nomegesrolu
NO20054897L (no) Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav
US7338663B2 (en) Expandable osmotic composition and coating suspension
CN115038451A (zh) 多模式组合物和治疗方法
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
BRPI0405662A (pt) Emplastros contendo turobuterol

Legal Events

Date Code Title Description
FC Refusal